Results 61 to 70 of about 17,111 (223)
Clinical Profile and Treatment Outcomes of Tumour-Induced Osteomalacia – A Single-Centre Experience
Introduction: Tumour-induced osteomalacia (TIO) is rare. At our referral centre, we see a substantial number of TIO. Therefore, we planned to study their profile and treatment outcomes to provide insight in management.
Prashiddha Dhakal +9 more
doaj +1 more source
Fibroblast growth factor 23 (FGF23) could contribute to cardiovascular morbidity in chronic kidney disease. In studies of kidney transplant recipients, a high circulating level of FGF23 has been associated with death and graft loss independently of ...
Frank Bienaimé +8 more
doaj +1 more source
Fibroblast Growth Factor-23—A Potential Uremic Toxin
Fibroblast growth factor-23 (FGF23) is a circulating member of the FGF family produced mainly by the osteocytes and osteoblasts that can act as a hormone.
Piotr Kuczera +2 more
doaj +1 more source
Self‐Assembling Hybrid Hydrogel Reprograms the Stromal Vascular Fraction to Treat Osteoarthritis
This study presents a bioinspired injectable hydrogel that enhances the therapeutic potential of stem cell‐rich stromal vascular fraction for treating osteoarthritis. By reprogramming cell behavior through epigenetic modulation, the hydrogel promotes cartilage regeneration and reduces joint damage in a rat model, offering a promising new approach for ...
Waifang Hou +23 more
wiley +1 more source
FGF23-related hypophosphatemic rickets/osteomalacia: diagnosis and new treatment.
FGF23 is a phosphaturic hormone produced by bone. FGF23 reduces serum phosphate by suppressing proximal tubular phosphate reabsorption and intestinal phosphate absorption.
S. Fukumoto
semanticscholar +1 more source
Parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF23) both influence blood phosphate levels by regulating urinary phosphate reabsorption. Clinical data suggest that adequate renal phosphate handling requires the presence of both FGF23 and PTH,
D. Ovejero +6 more
semanticscholar +1 more source
FGF23 tumor induced osteomalacia
Tumor induced osteomalacia is a rare acquired disease. The cause is a mesenchymal tumor secreting fibroblast growth factor 23 (FGF23). An excessive amount of FGF 23 disrupts the metabolism of phosphorus and vitamin D, which leads to severe paraneoplastic syndrome, manifested in the form of multiple fractures, severe pain in the bones and generalized ...
S. A. Gronskaia +2 more
openaire +2 more sources
A DLN dataset was built to analyze MABS composition versus in vitro/in vivo osteogenesis and angiogenesis. An MLP neural network, taking BG morphological parameters as input, extracts bioactive features from these datasets. A rabbit tibial defect model then validates 4D‐printed MABS for adaptability and bone regeneration in critical defects.
Xiongjie Liang +12 more
wiley +1 more source
Fibroblast growth factor 23 (FGF23) is a phosphate regulating protein hormone released by osteocytes. FGF23 becomes markedly elevated in chronic kidney disease (CKD), for which the leading cause of death is cardiovascular disease, particularly sudden ...
Jonah M. Graves +7 more
semanticscholar +1 more source
Objective Systemic lupus erythematosus (SLE) shows clinical and molecular heterogeneity, and cardiovascular (CV) complications and lupus nephritis (LN) remain leading causes of morbidity and mortality. This study investigated whether omic profiling can reveal molecular endotypes linked to these outcomes.
Tomás Cerdó +84 more
wiley +1 more source

